Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
Department of Pharmacy, Fujita Health University Hospital , Toyoake , Japan.
Kaori
K
Ito
Masataka
M
Okamoto
Maiko
M
Ando
Yukiko
Y
Kakumae
Akinao
A
Okamoto
Yoko
Y
Inaguma
Masutaka
M
Tokuda
Masamitsu
M
Yanada
Shigeki
S
Yamada
Nobuhiko
N
Emi
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D018655:Lymphocyte Count; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D000069283:Rituximab / Q000008:administration & dosage; D016896:Treatment Outcome
D000069283:Rituximab; D000069461:Bendamustine Hydrochloride